Trial Profile
A clinical proof-of-concept study investigating the biochemical effect of RLBN1001 in patients with gout
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 28 Nov 2018
Price :
$35
*
At a glance
- Drugs RLBN 1001 (Primary)
- Indications Gout
- Focus Pharmacodynamics; Proof of concept
- 01 Sep 2018 According to a Acquist Therapeutics website, Relburn Metabolomics changed its name to Acquist Therapeutics.
- 28 Aug 2015 New trial record